: Since early May 2022, some monkeypox virus (MPXV) infections have been reported from countries where the disease is not endemic. Within 2 months, the number of patients has increased extensively, becoming the most considerable MPXV outbreak described. Smallpox vaccines demonstrated high efficacy against MPXVs in the past and are considered a crucial outbreak control measure. However, viruses isolated during the current outbreak carry distinct genetic variations, and the cross-neutralizing capability of antibodies remains to be assessed. Here we report that serum antibodies elicited by first-generation smallpox vaccines can neutralize the current MPXV more than 40 years after vaccine administration.
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II / Criscuolo, Elena; Giuliani, Benedetta; Ferrarese, Roberto; Ferrari, Davide; Locatelli, Massimo; Clementi, Massimo; Mancini, Nicasio; Clementi, Nicola. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 1096-9071. - 95:3(2023), p. e28643. [10.1002/jmv.28643]
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II
Ferrari, Davide;
2023-01-01
Abstract
: Since early May 2022, some monkeypox virus (MPXV) infections have been reported from countries where the disease is not endemic. Within 2 months, the number of patients has increased extensively, becoming the most considerable MPXV outbreak described. Smallpox vaccines demonstrated high efficacy against MPXVs in the past and are considered a crucial outbreak control measure. However, viruses isolated during the current outbreak carry distinct genetic variations, and the cross-neutralizing capability of antibodies remains to be assessed. Here we report that serum antibodies elicited by first-generation smallpox vaccines can neutralize the current MPXV more than 40 years after vaccine administration.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
